Functional selectivity in CB 2 cannabinoid receptor signaling and regulation: Implications for the therapeutic potential of CB 2 ligands

Molecular Pharmacology

Volumn 81, Issue 2, 2012, Pages 250-263

  Atwood, Brady K ^a   Wager Miller, James ^a   Haskins, Christopher ^a   Straiker, Alex ^a   Mackie, Ken ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMA PROTEIN;

ACUTE HEART FAILURE; ADVERSE OUTCOME; ARTICLE; BLOOD PRESSURE; COMORBIDITY; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; LIPID BLOOD LEVEL; MEDICAL RECORD REVIEW; META ANALYSIS; MORTALITY; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE BLIND PROCEDURE; SYSTOLIC DYSFUNCTION;

BENZOXAZINES; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; DRUG DESIGN; ENDOCYTOSIS; HUMANS; LIGANDS; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; NAPHTHALENES; PROTEIN TRANSPORT; RECEPTOR, CANNABINOID, CB2; SUBSTRATE SPECIFICITY;

EID: 84856068852     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.074013     Document Type: Article

References (54)

1. Anand P, Whiteside G, Fowler CJ, and Hohmann AG (2009) Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60:255-266.
2. Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, and Cullen MG (1997) Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 coreceptor. EMBO J 16:4606-4616. (Pubitemid 27326598)
3. Atwood BK, Huffman J, Straiker A, and Mackie K (2010) JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585-593.
4. Atwood BK, Lee D, Straiker A, Widlanski TS, and Mackie K (2011) CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB1 cannabinoid receptor agonists. Eur J Pharmacol 659:139-145.
5. Atwood BK and Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467-479.
6. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, and Vogel Z (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375:143-147.
7. Benito C, Kim WK, Kim WK, Chavarría I, Hillard CJ, Mackie K, Tolón RM, Williams K, Williams K, and Romero J (2005) A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virusinduced encephalitis. J Neurosci 25:2530-2536. (Pubitemid 40365164)
8. Berdyshev EV (2000) Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108:169-190.
9. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, Sun SC, Resnick L, Chlenov M, He Y, et al. (2007) Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151:1061-1070. (Pubitemid 47195523)
10. Blankman JL, Simon GM, and Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347-1356. (Pubitemid 350257008)
11. Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V, Parolaro D, Ross RA, Gauson LA, Cascio MG, et al. (2010) The plant cannabinoid Delta9- tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160:677-687.
12. Bouaboula M, Dussossoy D, and Casellas P (1999) Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 274:20397-20405.
13. Brown SM, Wager-Miller J, and Mackie K (2002) Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 1576:255-264. (Pubitemid 34655768)
14. Cabral GA and Griffin-Thomas L (2009) Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11:e3.
15. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, and Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376. (Pubitemid 32743923)
16. Daigle TL, Kearn CS, and Mackie K (2008) Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 54:36-44. (Pubitemid 350299401)
17. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
18. Finn AK and Whistler JL (2001) Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32:829-839. (Pubitemid 34024844)
19. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P, Rochette C, Sawyer N, Slipetz DM, Tremblay N, et al. (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6:2263-2268. (Pubitemid 26328497)
20. Griffin G, Tao Q, and Abood ME (2000) Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292:886-894. (Pubitemid 30136579)
21. Grimsey NL, Goodfellow CE, Dragunow M, and Glass M (2011) Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11- dependent pathway. Biochim Biophys Acta 1813:1554-1560.
22. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202. (Pubitemid 34575709)
23. Hsieh C, Brown S, Derleth C, and Mackie K (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73:493-501. (Pubitemid 29339821)
24. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, and Frank RA (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322-328. (Pubitemid 32299527)
25. Huffman JW, Dong D, Martin BR, and Compton DR (1994) Design, Synthesis and Pharmacology of Cannabimimetic Indoles. Bioorganic & Medicinal Chemistry Letters 4:563-566. (Pubitemid 24131892)
26. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, et al. (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100:10529-10533. (Pubitemid 37071912)
27. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, and Glass M (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67:1697-1704. (Pubitemid 40594170)
28. Khanolkar AD, Lu D, Ibrahim M, Duclos RI Jr, Thakur GA, Malan TP Jr, Porreca F, Veerappan V, Tian X, George C, et al. (2007) Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 50:6493-6500. (Pubitemid 350309089)
29. Koch T and Höllt V (2008) Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther 117:199-206.
30. Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N, Beyer A, Grecksch G, and Höllt V (2005) Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol 67:280-287. (Pubitemid 40069989)
31. Ligresti A, Cascio MG, and Di Marzo V (2005) Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord 4:615-623. (Pubitemid 41782623)
32. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, et al. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37-44.
33. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168:299-325.
34. Miller AM and Stella N (2008) CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153:299-308.
35. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G, Wotjak CT, Lutz B, and Marsicano G (2007) Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 5:e269.
36. Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S, Meyer M, and Yao BB (2004) Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol 505:1-9. (Pubitemid 39535670)
37. Pradhan AA, Befort K, Nozaki C, Gavériaux-Ruff C, and Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32:581-590.
38. Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, and Hohmann AG (2011) Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav 98:493-502.
39. Rajagopal S, Rajagopal K, and Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386.
40. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, and Pertwee RG (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672. (Pubitemid 29087845)
41. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan DJ, and Scott RH (2001) Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40:221-232.
42. Schuehly W, Paredes JM, Kleyer J, Huefner A, Anavi-Goffer S, Raduner S, Altmann KH, and Gertsch J (2011) Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem Biol 18:1053-1064.
43. Shoemaker JL, Ruckle MB, Mayeux PR, and Prather PL (2005) Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther 315:828-838. (Pubitemid 41509039)
44. Tao Q and Abood ME (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285:651-658. (Pubitemid 28237444)
45. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, and Pertwee RG (2005) Evidence that the plant cannabinoid Delta9- tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917-926. (Pubitemid 41722163)
46. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
47. von Zastrow M, Svingos A, Haberstock-Debic H, and Evans C (2003) Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate drugs. Curr Opin Neurobiol 13:348-353. (Pubitemid 36792248)
48. Whistler JL, Chuang HH, Chu P, Jan LY, and von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23:737-746. (Pubitemid 29411563)
49. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, and Winter J (2005) Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135:235-245. (Pubitemid 41219752)
50. Wu DF, Yang LQ, Goschke A, Stumm R, Brandenburg LO, Liang YJ, Höllt V, and Koch T (2008) Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J Neurochem 104:1132-1143. (Pubitemid 351143650)
51. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, and Gardner EL (2011) Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci 14:1160-1166.
52. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, et al. (2009) Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl- cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)- ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328:141-151.
53. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, and Anand P (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6:12.
54. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, and O'Donnell D (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17:2750-2754. (Pubitemid 36819300)